Recombinant Human TIGIT (T103) Fc Chimera Protein, CF

When Recombinant Human CD155/PVR (Catalog # 2530‑CD) iscoated at 2.5 µg/mL (100 μL/well), Recombinant Human TIGIT Fc Chimera(Catalog # 9464‑TG) binds with a typical ED50 of 8-48 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human TIGIT (T103) Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human CD155/PVR (Catalog # 2530‑CD) is coated at 2.5 μg/mL (100 μL/well), the concentration of Recombinant Human TIGIT (T103) Fc Chimera that produces 50% optimal binding response is typically 8-48 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human TIGIT protein
  

  Human TIGIT (Met22-Pro141, T103) Accession # Q495A1-1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q495A1-1
• N-terminal Sequence: Met22
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 40 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 44-60 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TIGIT (T103) Fc Chimera Protein, CF

• T cell immunoreceptor with Ig and ITIM domains
• TIGIT
• VSIG9
• VSTM3
• WUCAM

Background

TIGIT (T cell Immunoreceptor with Ig and ITIM domains), also called Vstm3 (V-set and transmembrane domain-containing 3), Vsig9 (V-set and Ig domain-containing 9) and WUCAM (Washington University cell adhesion molecule) is a 30-34 kDa type I transmembrane protein that is a member of the CD28 family within the Ig superfamily of proteins (1-4). Human TIGIT cDNA encodes 244 amino acids (aa) including a 21 aa signal sequence, a 120 aa extracellular region with a V-type Ig-like domain and two potential N-glycosylation site, a 21 aa transmembrane sequence, and an 82 aa cytoplasmic domain with an ITIM motif (5). A 170 aa variant diverges after aa 166 (5). Within the ECD, human TIGIT shares only 68-75% aa sequence identity with mouse, porcine, canine, equine and bovine TIGIT (1, 2). Binding of TIGIT by DC induces IL-10 release and inhibits IL-12 production (2). Ligation of TIGIT on T cells down‑regulates TCR-mediated activation and subsequent proliferation, while NK cell TIGIT ligation blocks NK cell cytotoxicity (6-8). Through CD155 and Nectin-2, which also interact with DNAM-1/CD226 and CD96/Tactile, TIGIT is part of an interacting network of Ig superfamily members that may augment or oppose each other (3, 4, 6, 7). In particular, TIGIT binding to CD155 can antagonize the effects of DNAM-1 (6, 7). Soluble TIGIT is able to compete with DNAM-1 for CD155 binding and attenuates T cell responses, while mice lacking TIGIT show increased T cell responses and susceptibility to autoimmune challenges (2, 3, 8).

1. Boles, K.S. et al. (2009) Eur. J. Immunol. 39:695.
2. Yu, X. et al. (2009) Nat. Immunol. 10:48.
3. Levin, S.D. et al. (2011) Eur. J. Immunol. 41:902
4. Xu, Z. et al. (2010) Cell. Mol. Immunol. 7:11.
5. SwissProt Accession # Q495A1.
6. Seth, S. et al. (2009) Eur. J. Immunol. 39:3160.
7. Stanietsky, N. et al. (2009) Proc. Natl. Acad. Sci. USA 106:17858.
8. Joller, N. et al. (2011) J. Immunol. 83:1338.

Bioinformatics

• Uniprot:
  • Q495A1-1()